This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01228/identifier/national-drug-code-directory/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/mesh/concept/
n13http://linked.opendata.cz/resource/drugbank/company/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01228/identifier/chebi/
n19http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB01228/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01228/identifier/pharmgkb/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01228/identifier/kegg-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01228/identifier/drugbank/
n17http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01228
rdf:type
n3:Drug
n3:description
All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.
n3:group
approved withdrawn
n3:halfLife
1-2 hours
n3:indication
Encainide is a class Ic antiarrhythmic agent which was used for management of irregular heartbeats, such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation.
owl:sameAs
n19:DB01228 n20:DB01228
dcterms:title
Encainide
adms:identifier
n7:C06978 n8:0087-0732-41 n9:Encainide n10:4788 n11:DB01228 n12:PA449459
n3:mechanismOfAction
Encainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole.
n3:packager
n13:271B5A5F-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
A radiolabeled dose of encainide is excreted in approximately equal amounts in the urine and feces.
n3:synonym
Encainida Encainide (+-)-4-Methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide 4-Methoxy-2'-[2-(1-methyl-2-piperidyl)ethyl]benzanilide 4-Methoxy-N-{2-[2-(1-methyl-piperidin-2-yl)-ethyl]-phenyl}-benzamide (+-)-2'-[2-(1-Methyl-2-piperidyl)ethyl]-P-anisanilide Encainidum
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Encainide.htm
n14:hasConcept
n15:M0025437
n3:IUPAC-Name
n4:271B5A64-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5A6A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5A69-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5A66-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5A67-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5A68-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5A62-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5A7A-363D-11E5-9242-09173F13E4C5 n4:271B5A60-363D-11E5-9242-09173F13E4C5 n4:271B5A63-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5A61-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n17:C01BC08
n3:H-Bond-Acceptor-Count
n4:271B5A70-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5A71-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5A6B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5A6C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5A6E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5A6D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5A6F-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
66778-36-7
n3:category
n3:Bioavailability
n4:271B5A76-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5A78-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5A79-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5A75-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5A74-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5A77-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5A65-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5A72-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5A73-363D-11E5-9242-09173F13E4C5